NCAM1 and neoplasm: Vitamin D supplementation, compared with placebo, significantly reduced the risk of relapse by 65% in the subgroup of patients with the higher half of CD56+ in tumor stroma, but it did not change it in the lower half, suggesting a significant interaction between vitamin D supplementation and CD56+ cells.